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Leishmaniasis has several clinical forms: self-healing or chronic cutaneous leishmaniasis
or post-kala-azar dermal leishmaniasis; mucosal leishmaniasis; visceral leishmaniasis (VL),
which is fatal if left untreated.The epidemiology and clinical features of VL vary greatly due
to the interaction of multiple factors including parasite strains, vectors, host genetics, and
the environment. Human immunodeficiency virus infection augments the severity of VL
increasing the risk of developing active disease by 100–2320 times. An effective vaccine
for humans is not yet available. Resistance to chemotherapy is a growing problem in many
regions, and the costs associated with drug identification and development, make com-
mercial production for leishmaniasis, unattractive.The toxicity of currently drugs, their long
treatment course, and limited efficacy are significant concerns. For cutaneous disease,
many studies have shown promising results with immunotherapy/immunochemotherapy,
aimed to modulate and activate the immune response to obtain a therapeutic cure. Nowa-
days, the focus of many groups centers on treating canine VL by using vaccines and
immunomodulators with or without chemotherapy. In human disease, the use of cytokines
like interferon-γ associated with pentavalent antimonials demonstrated promising results
in patients that did not respond to conventional treatment. In mice, immunomodulation
based on monoclonal antibodies to remove endogenous immunosuppressive cytokines
(interleukin-10) or block their receptors, antigen-pulsed syngeneic dendritic cells, or biolog-
ical products like Pam3Cys (TLR ligand) has already been shown as a prospective treatment
of the disease. This review addresses VL treatment, particularly immunotherapy and/or
immunochemotherapy as an alternative to conventional drug treatment in experimental
models, canine VL, and human disease.
Keywords: visceral leishmaniasis, immunology, immunotherapy, immunochemotherapy, Leishmania infantum,
Leishmania donovani
INTRODUCTION OF VISCERAL LEISHMANIASIS:
EPIDEMIOLOGY OF A ZOONOTIC AND ANTHROPONOTIC
NEGLECTED DISEASE
Visceral leishmaniasis (VL) is a severe chronic systemic disease
caused by Leishmania donovani or L. infantum. Occasionally, L.
tropica in the Middle East and L. amazonensis in South America
can produceVL (1). Leishmania spp. are transmitted to human and
animal hosts through the bite of female sand flies from the genera
Phlebotomus in the Old World and Lutzomyia in the New World
(2). Depending on whether or not a reservoir host is present, there
are two basic types of epidemiological cycles: zoonotic, generally
caused by L. infantum, which occurs in the Mediterranean Basin,
China, the Middle East, and South America, and anthroponotic,
generally caused by L. donovani, which is prevalent in East Africa,
Bangladesh, India, and Nepal (3). The dogs, independent of the
clinical form of VL, are the main urban reservoirs of L. infantum
and represent the major source of contagion for the vectors by
virtue of the high prevalence of infection and intense cutaneous
parasitism (4, 5).
Canine visceral leishmaniasis (CVL) is present in approximately
50 countries, mainly in South America, the Mediterranean region,
and Africa (6, 7). Several reports have revealed the emergence of
canine infection in new locations, such as the United States and
Canada (8, 9), and a northward spread in Europe, as found in
Italy (10, 11). The seroprevalence of CVL ranges between 2 and
25% in endemic areas of Europe (2) and 5.9 and 29.8% in Brazil
(12). In recent years, with the development of molecular tech-
niques, infection rates have been shown to be underestimated.
Studies in Europe have demonstrated an elevated prevalence of
CVL (60–80%) by polymerase chain reaction (PCR) compared
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with serology (25%) (13). During a cross-sectional study in an
urban area of Brazil, we observed that approximately a quarter
of seronegative dogs were infected by L. infantum according to
PCR (14), and they had approximately twice the risk of sero-
conversion as those that were PCR negative (15). Finally, a high
incidence of infection was demonstrated by PCR in endemic
areas (16).
Official global estimates indicate that there are more than
58,000 cases of human VL (HVL) per year. However, the num-
ber may actually be as high as 0.2–0.4 million, and more than
90% of cases occur in five countries: India, Bangladesh, Sudan,
Brazil, and Ethiopia (17). The incidence of VL is relatively low in
southern Europe (2), but the disease has recently spread further
northward as shown by reports of cases in northern Italy (18) and
Germany (19). Additionally, the epidemiology of the disease has
been influenced by the expansion of human immunodeficiency
virus (HIV). Of the 70 countries that are endemic for VL, 35
have reported cases of Leishmania–HIV co-infection (20). One
of the critical complications associated with co-infection is that
HIV reduces the likelihood of a therapeutic response to treatment
against L. infantum, and it also greatly increases the probability of
a relapse (21).
Visceral leishmaniasis is clinically characterized by pro-
longed fever, weakness, anorexia, weight loss, hepatomegaly,
splenomegaly, hypergammaglobulinemia, and pancytopenia.
Without treatment, the disease may progress over time to severe
cachexia, multisystem disease, bleeding, secondary infections,
and death (22, 23). The case-fatality rates range from 1.5% in
Bangladesh to 2.4% in India and 6.2% in Nepal (17). However,
studies conducted by Ahluwalia et al. (24) in Bangladesh and
by Barnett et al. (25) in India suggest that the rates are proba-
bly underestimated. In Brazil, data from the Ministry of Health
were used to estimate 6.5% mortality from 2001 to 2011 (26).
VL results in death mainly in untreated patients. The majority of
leishmaniasis deaths go unrecognized, and even with treatment
access, case-fatality rates can be as high as 10–20% (17). These
findings underscore the need for further studies on the develop-
ment of immunotherapeutic and prophylactic strategies for VL
and Leishmania–HIV co-infection.
In this review, we discuss the recent advances in immunother-
apy and immunochemotherapy in the treatment of VL, focusing
on both canine and human disease and experimental models
(murine). We also discuss some aspects of the epidemiology and
immunology of VL, the most recent strategies and guidelines for
chemotherapy, and new advances in modulating the host immune
response (collectively called immunotherapy) with or without
conventional chemotherapy.
IMMUNOBIOLOGY OF VISCERAL LEISHMANIASIS: CELLS
AND IMMUNE MEDIATORS RELATED TO RESISTANCE AND
SUSCEPTIBILITY
In visceral disease, the immunology and immunopathology in
humans, dogs, and experimental rodent models has been exten-
sively studied, with many points characterized and others still to be
elucidated (27–29). A general consensus is that despite the pecu-
liarities of each model, the outcome of the disease is critically
influenced by the host immune response.
Several studies have demonstrated that susceptibility to HVL is
related to a high titer of circulating antibodies and a depression
of type-1 T cell-mediated immunity, mainly with decreased pro-
duction of interferon (IFN)-γ and interleukin (IL)-12, including
a marked up-regulation of IL-4 and IL-10 cytokines (30–32). In
CVL, the protective response has also been associated with activa-
tion of Th1 cells producing IFN-γ, IL-2, and tumor necrosis factor
(TNF)-α (33, 34). Similar to HVL, active CVL is characterized
by polyclonal B-cell activation, specific immunosuppression, and
the appearance of clinical symptoms depending on the parasite
density in different visceral organs (35, 36). An interplay of Th1
and Th2 cytokines appears to exist during Leishmania infection,
and this suggests important roles for different cytokines in disease
protection and pathogenesis (37).
The innate immune response contributes to VL resistance, act-
ing to control parasite growth during the early stages of infection.
Furthermore, it directs cell recruitment and helps develop the
cytokine microenvironment in which parasite-specific T cells are
primed (38, 39).
The control of VL infection depends on a successful cell-
mediated immune response (40), in which IFN-γ, produced
mainly by CD4+ T cells and natural killer (NK) cells stimulated
by IL-12, leads to stimulation of microbicide action mediated by
nitric oxide (41, 42). TNF-α exerts cytotoxic effects on invading
parasites via its receptor, TNFR (43). There have been reports
of the involvement of different Th17 cytokines in HVL, includ-
ing IL-17, IL-22 (44), and IL-21 (45), which are important in
the migration, recruitment, and activation of neutrophils. Recent
work of Gautam et al. (46) evaluating patients with VL showed
that individuals with active disease exhibit predominantly anergic
splenic CD8 cells and CD8 peripheral blood mononuclear cells
(PBMCs) with a mixture of anergic cells and cytotoxic T lym-
phocytes (CTLs). Following a cure after treatment, CD8 T cells
contribute to Leishmania-induced IFN-γ production. The authors
suggested that CD8 T cells are driven to anergy/exhaustion in
HVL, which affects their ability to launch a protective immune
response (46).
The expression of the various chemokine genes is observed
in Leishmania infection (47, 48). Chemokines have been shown
to play a crucial role in determining the outcome of leishmania-
sis by coordinating the leukocyte recruitment involved in innate
and adaptive immune responses (49, 50). Patients with VL show
elevated concentrations of CXCL9 and CXCL10 in their serum
during active infection, and it has been suggested that these
chemokines play an important role along with IFN-γ in the disease
(51). Dogs naturally or experimentally infected with L. infan-
tum have CXCL10 mRNA overexpressed in the spleen, leading
to a substantial type-1 immune response (52). A detailed analy-
sis of chemokine expression in skin samples from dogs naturally
infected with L. infantum demonstrated enhanced parasite density
and a positive correlation with CCL2, CCL4, CCL5, CCL21, and
CXCL8 (49). It is noteworthy that some chemokines such as CCL2
can activate macrophages to participate in reducing the parasite
load (53).
The monocytes/macrophages, the main targets of Leishmania,
represent one of the first steps of the innate immune response to
kill intracellular parasite (54). The survival of the parasite relies
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on evasion mechanisms such as the modulation of leishmanicidal
activity of macrophages by production of tumor growth factor
(TGF)-β with deactivation, inhibition of the action of IFN-γ,
reduced expression of MHC class II molecules, and suppres-
sion of nitric oxide production (55). IL-10 is another cytokine
produced by macrophages that contributes to the survival of
Leishmania in these cells, and it has emerged as the most potent
factor for VL pathogenesis. It inhibits synthesis of cytokines pro-
duced by macrophages, such as IL-1β, IL-6, IL-8, and TNF-α
(56) and reduces the antigen-presenting function of these cells
by decreasing the expression of MHC class II molecules (57). The
association of IL-10 and VL in humans with active disease is well-
established (32). Others cytokines, such as IL-27 and IL-21, have
also emerged as being implicated in disease progression through
the regulation of IL-10 (45). Other cells, such as NK cells, are
important components of the immune response to combat infec-
tion. They connect the innate response to the development of
efficient adaptive cellular immunity, mainly through TNF-α and
IFN-γ production (58).
Successful immunity against Leishmania involves a complex
immunological response of several mechanisms and factors,
including the migration of appropriate cell populations to the
infected sites, cytokine microenvironment, chemokines, and oth-
ers. The elucidation and a better understanding of the immune
response against Leishmania infection are relevant to establish a
rational approach for immunomodulatory therapy and vaccine
development.
CONVENTIONAL VL THERAPY
The drug policy in endemic countries and therapeutic decisions
should be based on the individual benefit–risk ratio of drugs, the
health service setting, and the availability of anti-leishmanial med-
icines in the context of public health concerns and the difference
of the VL epidemiological aspects (anthroponotic and zoonotic)
(59). For example, 70% of the anthropozoonotic VL burden occurs
in the Indian subcontinent (17), and a critical challenge is related
to widespread resistance to pentavalent antimony; resistance rates
approach 60% in Bihar, India (60). In Europe, Asia, Africa, and the
Americas, where zoonotic cases are observed, the risk of human
disease is well-known to be associated with canine infection rates
(61). Another serious problem that mainly occurs with zoonotic
VL is that canine treatment does not effectively lead to a parasito-
logical cure since these animals are constant sources of infection
for sand flies (36).
Nevertheless, a few drugs are available. In most cases, the first-
line treatment is pentavalent antimonials, and amphotericin B or
pentamidine are commonly employed as second-line medicines.
In recent years, other medicines have been extensively studied and
became invaluable, such as liposomal amphotericin B (62), milte-
fosine (63, 64), and paromomycin (65). In line with this, current
World Health Organization (WHO) treatment advice varies by
global region, which is partially explained by differences in par-
asite susceptibility (59, 66, 67) (Table 1). Even so, the number
of VL cases is increasing worldwide, and the enduring problems
with current chemotherapy tools are still a critical issue. Further-
more, in many developing countries the cost of treatment is the
greatest challenge faced by health authorities (Table 2). In the
following section, we briefly review conventional chemotherapy,
stressing essential issues in HVL and studies using different drugs
and strategies for canine disease.
PENTAVALENT ANTIMONIALS
It is generally accepted that pentavalent antimonials (SbV) are the
pro-drug, and that they must convert to trivalent antimonials
(SbIII) to have anti-leishmanial activity. The issues with the use
of this drug are commonly attributed to serious side effects such
as cardiotoxicity (68), pancreatitis (69), and nephrotoxicity (70).
The doses and treatment durations of SbV have undergone con-
stant changes over the years. The use of SbV in canine therapy
does not lead to clinical and parasitological cure (71), and dis-
ease relapses are common (72). Moreover, prolonged or repeated
use of this drug can induce resistance in Leishmania clones (73).
Currently, an important strategy for therapy in dogs is the use
of liposome-encapsulated SbV, which promotes improved clinical
status and reduced parasite load in infected animals (74).
AMPHOTERICIN B DEOXYCHOLATE AND LIPOSOMAL
AMPHOTERICIN B
The anti-Leishmania activity by amphotericin B is due to its
complexation with 24-substituted sterols such as ergosterol and
episterol, which are predominant in the plasma membranes of
parasites. Amphotericin B deoxycholate is generally used for cases
that are unresponsive to SbV, and it is a first-line drug in India.
Unresponsiveness and relapses occur rarely and mostly in relation
to HIV co-infection (75). The major limitation to using this drug is
the necessity for prolonged hospitalization and close monitoring
due to its high nephrotoxicity (76). The liposomal formulation
improves the safety profile of amphotericin B and increases the
anti-leishmanial activity, with selectivity to macrophage reticular–
endothelial system (77). There are three formulations, liposomal
amphotericin B, amphotericin B lipid complex, and amphotericin
B cholesterol dispersion; all of which ensure a decrease in nephro-
toxicity. Currently, liposomal amphotericin B is the first treatment
choice for HVL in several endemic countries in Europe as well
as in the United States. Following other countries, the Ministry
of Health in Brazil, expanded the use of this medicine in the last
years. In dogs, therapy with amphotericin B deoxycholate reduces
serum antibody levels and parasite loads and increases the lym-
phoproliferative response, but the effects are transitory (78). In
addition, renal failure is a common outcome (79), and the drug is
not recommended for canine therapy. Treatment with liposomal
amphotericin B resulted in recovery in dogs, but despite the initial
effectiveness, relapses can occur (78, 80).
MILTEFOSINE
Miltefosine, which was initially developed as an anticancer drug,
is the first effective oral drug for VL, and it represents a great
breakthrough (81, 82). The main anti-leishmanial activity is due
to modulation of cell surface receptors, inositol metabolism, phos-
pholipase activation, and protein kinase C in addition to mitogenic
pathways resulting in apoptosis (83). The main side effects of the
drug include gastrointestinal disturbances, but the symptoms are
transient or reversible; however, teratogenicity is a major problem
(84). Careful use of this drug should be mandatory, since resistance
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Table 1 | Recommendations of the World Health Organization for the treatment of visceral leishmaniasis per geographic region ranked by
preference [World Health Organization (59)].
ANTHROPONOTIC VISCERAL LEISHMANIASIS CAUSED BY L. donovani INTHE INDIAN SUBCONTINENT
Liposomal amphotericin B: 3–5 mg/kg daily over 3–5 days to a total dose of 15 mg/kg by infusion or 10 mg/kg as a single dose
Combination therapy (co-administered following the sequence): (i) liposomal amphotericin B (5 mg/kg by infusion, single dose)+miltefosine (daily for
7 days, dosage as below), (ii) liposomal amphotericin B (5 mg/kg by infusion, single dose)+paromomycin (daily for 10 days, dosage as below), (iii),
miltefosine+paromomycin both for 10 days (dosages as below)
Amphotericin B deoxycholate: 0.75–1.0 mg/kg daily or on alternate days for 15–20 doses by infusion
Miltefosine: children aged 2–11 years, 2.5 mg/kg daily; 12 years and older <25 kg body weight, 50 mg/day; 25–50 kg, 100 mg/day; >50 kg, 150 mg/day;
orally for 28 days
Paromomycin: 15 mg (11 mg base)/kg/day by intramuscular route for 21 days
Pentavalent antimonials: 20 mg SbV/kg/day intramuscularly or by infusion for 30 days (areas where they are effective: Bangladesh, Nepal, and the Indian
states of Jharkhand, West Bengal, and Uttar Pradesh)
VISCERAL LEISHMANIASIS CAUSED BY L. donovani IN EAST AFRICA
Combination therapy: pentavalent antimonials (20 mg SbV/kg/day intramuscularly or by infusion)+paromomycin [15 mg (11 mg base)/kg/day by
intramuscular route] for 17 days
Pentavalent antimonials: same treatment scheme as above
Liposomal amphotericin B: 3–5 mg/kg daily given over 6–10 days for a total dose of 30 mg/kg by infusion
Amphotericin B deoxycholate: same treatment scheme as above
Miltefosine: same treatment scheme as above
VISCERAL LEISHMANIASIS CAUSED BY L. infantum
Liposomal amphotericin B: 3–5 mg/kg daily over 3–6 days for a total dose of 18–21 mg/kg by infusion
Pentavalent antimonials: 20 mg SbV/kg/day intramuscularly or by infusion for 28 days
Amphotericin B deoxycholate: 0.75–1.0 mg/kg daily or on alternate days for 10–20 doses by infusion (total dose: 2–3 g)
can be easily induced in in vitro experiments (85). Miltefosine has
recently emerged as a potential tool for CVL treatment, and its
use has been evaluated in monotherapy and in combination with
other drugs (86, 87). There are no nephrotoxic effects reported,
and vomiting is the most common side effect in dogs (88).
PAROMOMYCIN
Paromomycin presents variable efficacy in distinct parts of the
world (89). The drug’s low-cost, relatively short duration of
administration, and good safety profile strengthens its usefulness
as a first-line drug (90). The drug has activity against Leishmania
by altering plasma membrane fluidity, interfering in ribosomal
function, and disrupting mitochondrial membrane potential (91).
The most common side effects associated with paromomycin are
ototoxicity and impaired liver function (92). Although it is the
least expensive drug for VL, current demand for paromomycin
is low, and production is irregular. In canine studies, the drug
was associated with a decrease in anti-Leishmania IgG antibody
titers (93). Following clinical recovery, relapse, and parasitologic
cure in symptomatic CVL treated with paromomycin, only clin-
ical improvement was verified (94). However, the search for an
optimum dosage for the safe use in the treatment of CVL is
necessary.
Table 2 | Cost of visceral leishmaniasis treatment (patient weighing
35 kg)*.
Medicine (compound) Treatment regimen
in days
Drug cost
in US$
L-Amb 10 mg/kg 1 125
L-Amb 20 mg/kg 2–4 250
Amphotericin B deoxycholate 1 mg/kg
(alternating days)
30 20
MF 100 mg/kg 28 65–150
PM 15 mg/kg/day 21 15
SSG 20 mg/kg/day 30 55
MA 20 mg/kg/day 30 59
L-Amb 5 mg/kg+MF 100 mg/kg 8 88–109
L-Amb 5 mg/kg+PM 15 mg/kg/day 11 78
MF 100 mg/kg+PM 15 mg/kg/day 10 30–60
SSG 20 mg+PM 15 mg/kg/day 17 43
*Calculations for SSG andMF based on exchange rate of C1=US$ 1.40 (Decem-
ber 2013). Price range of MF depends on order volume. Price is based on generic
SSG,World Health Organization (59).
L-Amb, liposomal amphotericin B; MF, miltefosine; PM, paromomycin; SSG,
sodium stibogluconate; MA, meglumine antimoniate.
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COMBINED DRUG THERAPY
In general, the treatment of VL is clinically challenging, and the
drugs have several drawbacks. Over the past few years, the WHO
consensus has evolved toward the use of combination regimens,
particularly in highly endemic regions. Combining drugs from
various chemical classes has the following objectives: (i) short-
ening the duration of treatment, reducing total parenteral drug
doses with fewer toxic effects, and improving adherence to the reg-
imen; (ii) lowering the cost of the treatment (less burden on the
health system), thus providing a more cost-effective option, and
(iii) helping to delay the emergence of resistance. These strate-
gies could increase the therapeutic lifespan of the respective drugs,
as has been demonstrated with drugs for diseases like malaria,
tuberculosis, and HIV. These strategies might also encourage a
cure, especially in complicated cases like Leishmania–HIV co-
infection, for which treatment outcomes with monotherapy have
been consistently poor (1, 59, 66).
Recently, reports of treatment failure with SbV from the Indian
subcontinent have increasingly raised the issue of acquired drug
resistance (67). This concern also extends to miltefosine, which
is worrisome given the drug’s long half-life (84). More recently
(95) reported unresponsiveness to liposomal amphotericin B in
Sudanese patients, who experienced cured disease only with com-
bination treatment. Specifically, a 17-day combination of antimo-
nials with paromomycin presented 93% efficacy in East Africa.
Combination regimens including liposomal amphotericin B (sin-
gle dose), paromomycin, and/or miltefosine were also found to be
extremely effective (98–99%) and safe, and are now included in
WHO guidelines for the Indian subcontinent (see Table 1) (1, 59).
Substantial progress has been made in the chemotherapeutic
approaches in recent years, but the current conventional drugs
for VL are far from ideal (96). Combined therapy enhancement
should be on-going, but exploratory studies that encompass highly
efficient regimens in single dose treatments are urgently needed
(97). The most effective strategies for protecting against resistance
are uncertain, but overall monitoring of access to anti-leishmanial
drugs should definitely be strengthened. In this context, canine
treatment is still controversial, and strict action should be taken
particularly for zoonotic VL. Worryingly, in Europe, dogs with
active VL are routinely treated with first-line drugs for HVL, and
this practice could generate parasites that are resistant to con-
ventional therapies (98). Considering the success of combined
therapy, the control and the effectiveness of current conventional
medicines must be protected until new options arise.
PROMISING STRATEGIES FOR VL TREATMENT:
IMMUNOTHERAPY AND IMMUNOCHEMOTHERAPY
The immunotherapy, involves the use of biological substances or
molecules to modulate the immune responses for the purpose
of achieving a prophylactic and/or therapeutic success. Currently,
immunotherapy is a strategy applied against various diseases such
as cancer, allergies, and some viruses (hepatitis). It is based on
the idea that our organism’s defense systems are capable of pro-
tecting us against a variety of diseases (in most circumstances).
Normally, it is known that disease occurs when there is either a
failure, suboptimal, or excessive immune response and this could
be remedied by appropriate immune modulation or interventions
using immunomodulatory agents or biological response modi-
fiers. Thus, immunotherapeutic agents can exert their effect by
directly or indirectly augmenting the host natural defenses, restor-
ing the impaired effectors functions or decreasing host excessive
response (99–101). Moreover, the combination of immunother-
apy with chemotherapeutic drugs (immunochemotherapy), espe-
cially when applied against infectious diseases, results in an
increased synergic action with activation of the immune system
and direct action of drugs against the infectious agent. Therefore,
immunotherapy and immunochemotherapy have been used to
accelerate the specific immunity in responsive and non-responsive
patients (102, 103). The underlying idea is to selectively induce
Th1 responses that are fundamental for resistance in VL. Pro-
tective immunity usually follows recovery from leishmaniasis in
immunocompetent patients, but the behavior of disease in these
individuals suggests that their immune responses are not sterile.
VL has emerged as an important opportunistic infection associated
with HIV, with the risk of developing active/severe disease increas-
ing 100–2320 times the average (20). Depending on the stage
of infection and the clinical condition, the use of conventional
chemotherapy can be inefficient. In such cases, combination ther-
apy with immunomodulators that potentiate the cellular immune
response can lead to more satisfactory results.
Immunotherapy with or without chemotherapy has been used
for the treatment of cutaneous leishmaniasis (CL) in the last two
decades. Convit et al. (104), using three injections of a vaccine
composed of a lysate of L. mexicana amazonensis with BCG as
an adjuvant, demonstrated a 94% of cure rates in CL patients
in Venezuela. These authors also showed that 5341 patients from
four different regions of Venezuela, who had different forms of
CL (mucosal and chronic CL) and received the vaccine treat-
ment between 1990 and 1999, demonstrated a high cure rate
(91.2–98.7%) (105). In Brazil, Mayrink et al. (106) evaluated an
immunotherapy protocol using a mixture of five strains of Leish-
mania vaccine and observed a 76% cure rate in patients with CL.
Moreover,years later,Mayrink et al. (107) used repeated daily doses
of killed L. amazonensis in a human clinical trial comprising 542
patients and observed that 98.1% of the individuals treated with
immunotherapy (n= 53; L. amazonensis vaccine+BCG) showed
a clinical cure. A similar cure rate was found in patients treated
with conventional chemotherapy and an immunochemotherapy
scheme (100%). The immunochemotherapy protocol was also
associated with a reduction in the total volume of the drug used
(17.9%) and a shorter treatment time (94.6 days for chemotherapy
alone to 64.7 days for immunochemotherapy) (107). In the Sudan,
a trial involving patients with persistent post-kala-azar dermal
leishmaniasis and using a vaccine composed of a mixture of killed
L. major adsorbed on alum+BCG, given four times at weekly
intervals, showed that the cure rate with immunochemotherapy
was significantly higher than with chemotherapy alone (final cure
rates: 87 and 53%, respectively) (108).
As we observed, therapeutic vaccines in CL can be rapidly eval-
uated at lower cost, appear to be safe, and are not associated
with the adverse effects of conventional treatment, encourag-
ing the use of this strategy for treatment of VL. Furthermore,
using immunomodulators to enhance host immunity combined
with conventional chemotherapy may have several advantages
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Table 3 | Immunotherapy and immunochemotherapy strategies against VL for humans and dogs.
Immunotherapeutic
agent
Chemotherapy
agent
Visceral
disease
Improvements Treatment
efficacy
Reference
IFN-γ SbV Human Accelerated parasitological control, enhanced the
clinical efficacy of conventional SbV treatment,
83.2% cure rate
Marked (109–111)
IFN-γ for 15 or 30 days
(107 U/mg/day)
SbV (20 mg/kg/day) at
30 days
Human No difference was observed in patients treated
with SbV alone
Moderate (112)
IFN-γ SbV (20 mg/kg/day) at
30 days
Human All patients responded clinically to treatment, more
quickly splenic culture-negative
Moderate (113)
Antigenic preparation of
L. infantum (soluble
antigen)
100 mg/kg SC of
N -methyl-d-glucamine
antimoniate
Canine Increase in the T lymphocytes, especially
CD4/TcRαβ+ and CD4/CD45RA+ cells in PBMC;
reduction of infection to Phlebotomus perniciosus
Low (114)
Enriched-Leishmune®
vaccine (plus 0.5 mg of
saponin)
n.d. Canine Higher levels of anti-FML IgG (IgG2), positive
delayed type hypersensitivity reaction, lower
clinical scores
Moderate (115, 116)
Enriched-Leishmune®
vaccine (plus 0.5 mg of
saponin)
Allopurinol (10 mg/kg)
and amphotericin B
(0.5 mg/kg)
Canine Positive DTH reaction, reduction of symptomatic
cases and low numbers of animals with parasites
in lymph nodes and deaths
Marked (117)
Vaccine composed by
20µg of
rLeish-110f®+25µg of
MPL-SE®
100 mg/kg/day IM of
Glucantime®
Canine Improvement in the clinical parameters
(hematological, biochemical, cellular); reduction in
parasitological positive animals (bone marrow
smears or culture); reduced number of deaths;
33% xenodiagnosis negative of by PCR
Marked (118)
Vaccine composed by
20µg of Leish-111f®
plus 20µg of MPL-SE®
20 mg/kg/day IV of
Glucantime®
Canine Cure rates 50%; 92% clinical improvement Moderate (119)
Immunomodulator
P-MAPA (2.0 mg/kg)
intramuscularly
n.d. Canine Increase CD8+ T cells, IL-2, and IFN-γ; decrease in
IL-10 and improvement in clinical signs and
reduction in parasite load in skin
Marked (120)
SC, subcutaneous; IM, intramuscular; IV, intravenous; n.d., not done.
as a means to improve current therapeutic regimens in this
neglected disease (109). On this topic, we discuss advances in
immunotherapy and immunochemotherapy for VL by focusing
mainly on approaches used in humans and dogs (Table 3) and
recent advances in murine models.
APPROACHES USED IN HUMANS
Increasing reports of treatment failure (SbV, miltefosine, and lipo-
somal amphotericin B) and complicated cases (Leishmania–HIV
co-infection) in HVL increase the urgency of using combination
therapies and developing new treatment strategies for the disease
(67, 95). In fact, the added effects produced by immunotherapy
and/or immunochemotherapy could be potentially useful against
HVL; however, these approaches are still very rarely used.
In this context, IFN-γ is well-recognized as a cytokine capable
of inducing macrophages to kill intracellular Leishmania (110). It
is clinically well-tolerated (111), and repeat treatment with IFN-γ
plus SbV has been shown to be effective in patients with SbV-
refractive disease, yielding a>80% cure rate in VL (112, 113, 121).
Studies in untreated patients with VL demonstrated that the addi-
tion of IFN-γ as immunotherapy accelerated parasitological con-
trol (122, 123) and enhanced the clinical efficacy of conventional
SbV therapy (123). However, another human trial in India showed
no differences among patients treated with SbV alone (30 days,
20 mg/kg/day), SbV plus IFN-γ (30 days, 107 U/mg/day), or SbV
plus IFN-γ for 15 days (114). Six months after treatment, a low
percentage of individuals were cured (36, 49, 42%, respectively),
but the immunochemotherapy protocol was the most efficient.
A similar study was conducted in Kenyan patients with VL
treated for 30 days with either conventional therapy with SbV or
immunochemotherapy (daily SbV plus IFN-γ) (122). All patients
responded clinically to treatment, and microscopic splenic aspi-
rate scores rapidly decreased in both groups. Interestingly, the
patients treated with immunochemotherapy had a negative spleen
culture more quickly, which may demonstrate the potential of
this protocol to accelerate early parasitological control (122).
These results suggest the beneficial effects of using IFN-γ in the
treatment of HVL. The combination of this immunotherapy or
Frontiers in Immunology | Immunotherapies and Vaccines June 2014 | Volume 5 | Article 272 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Roatt et al. Immunotherapy and immunochemotherapy in visceral leishmaniasis
another (therapeutic vaccines, immunomodulators) with other
drugs (miltefosine, liposomal amphotericin B) could provide more
satisfactory results with better cure rates mainly in VL patients
unresponsive to SbV.
PROGRESS FOR VL TREATMENT IN DOGS
The drugs generally used to treat CVL are highly toxic, expen-
sive, and ineffective. They promote clinical remission without
parasite reduction or sterilization, and once the treatment is with-
drawn, relapses of the disease are always observed (115). Moreover,
the WHO does not recommend the use of human chemother-
apy in dogs due to concerns about selecting for drug-resistant
parasites, which might then be untreatable in subsequent HVL
infection. Also, primary resistance to these drugs is considerable,
and treated dogs still have parasites in different organs even if they
are asymptomatic (116).
Along with vaccine development, new drugs and new treat-
ment strategies (immunotherapy and immunochemotherapy) are
the most important alternatives for CVL control. Guarga et al.
(117) evaluated the efficacy of a novel immunochemotherapy pro-
tocol in dogs naturally infected with L. infantum. The protocol
consisted of 21 consecutive subcutaneous injections of N -methyl-
d-glucamine antimoniate (100 mg/kg) and three applications of
an antigenic preparation of L. infantum (soluble antigen). The
animals showed an increase in the proportion of T lymphocytes,
especially of CD4/TcRαβ+ and CD4/CD45RA+ cells in PBMCs,
and reduction in the infection from Phlebotomus perniciosus after
immunochemotherapy (117).
Different studies are being done to evaluate the potential
of fucose–manose-ligand (FML) antigen plus saponin as an
immunotherapy. Borja-Cabrera et al. (118) used three vaccine
doses (1.5 mg FML+1 mg saponin) in asymptomatic dogs and
observed them for 22 months after immunotherapy was com-
plete. No deaths due to disease were recorded, and 90% of
the dogs remained asymptomatic, healthy, and parasite free.
In contrast, 37% of kala-azar deaths were recorded in non-
treated animals (118). Another vaccine formulation (enriched-
Leishmune® vaccine plus 0.5 mg of saponin) was evaluated by
Santos et al. (119) in dogs experimentally infected with L. infan-
tum. The enriched-Leishmune was injected when dogs were
seropositive and symptomatic. After immunotherapy, the dogs
showed higher levels of anti-FML IgG (higher IgG2 and lower
IgG1), positive delayed type hypersensitivity reactions, lower clin-
ical scores, and normal CD4+ counts (119). The association
of enriched-Leishmune vaccine with chemotherapy (allopurinol
or amphotericin B/allopurinol) demonstrated synergistic effi-
cacy in naturally infected animals. For both immunotherapy and
immunochemotherapy, dogs showed an intradermal response to
Leishmania antigen, reduction of symptomatic cases, a lower pro-
portion of animals presenting with parasites in lymph nodes, and
fewer deaths (120).
Miret et al. (124) evaluated immunochemotherapy using Leish-
110f®+MPL-SE® vaccine in combination with Glucantime®
and showed in symptomatic dogs improved clinical parame-
ters (hematological, biochemical, and immunological), reduced
parasite-positive animals, and reduced number of deaths com-
pared to control groups (adjuvant alone or placebo). Trigo et al.
(125) performed two separate trials to evaluate the recombinant
polyprotein vaccine antigen Leish-111f®, formulated with MPL-
SE® for therapeutic purposes against CVL. In both trials, a ther-
apeutic efficacy of the vaccine in preventing mild cases of disease
was demonstrated, and weekly injections (three doses) promoted
clinical cure for many dogs with VL.
Using an immunomodulator, Santiago et al. (126) tested
the immunotherapeutic effect for CVL of a protein aggregate
of magnesium–ammonium phospholinoleate–palmitoleate anhy-
dride (P-MAPA) obtained by fermenting the fungus Aspergillus
oryzae. P-MAPA showed immunomodulatory activity,with greater
stimulation of cellular immunity and no toxic effects in mice
and dogs (127). To investigate the immunotherapeutic poten-
tial of P-MAPA, symptomatic dogs were submitted to a protocol
of 15 doses of the immunomodulator (2.0 mg/kg) intramuscu-
larly. An increase in CD8+ T cells in peripheral blood, a decrease
in IL-10 levels, and an increase in IL-2 and IFN-γ, improved
clinical signs, and reduced skin parasitism were obtained after
immunotherapy (126).
Some CVL vaccines candidates have been developed by our
research group, called LBSap and LBSapSal, demonstrating impor-
tant results of immunogenicity and efficacy in phase I and II
trials (128, 129). Currently, we are investigating the potential
immunotherapeutic of these and other vaccines in the treat-
ment of CVL. Given these results, we believe that we could use
immunotherapy/immunochemotherapy to treat dogs in endemic
areas to eliminate their reservoir condition mainly by decreas-
ing the skin parasite load, which would block the zoonotic
transmission cycle.
RECENTS ADVANCES IN MURINE MODELS
With the current status of Leishmania treatment, use of a low-
dose drug or a short course of an effective drug in combination
with an immunomodulator is an approach for effective treat-
ment of disease (130). Thus, murine models of leishmaniasis
are being extensively used to obtain preliminary information on
the anti-Leishmania potential of different compounds (67). Many
researchers have worked on the development and discovery of new
agents against the parasite, and several studies have shown that the
use of immunotherapy would be an important tool in control
of VL.
Because SbV-based anti-leishmanial chemotherapy depends in
part on the Th1 response, which can be induced by dendritic
cell (DC)-based treatment (131). DC-based immunotherapy com-
bined with SbV chemotherapy was very effective against murine
VL (132). While three weekly injections of L. donovani-soluble,
antigen-pulsed syngeneic bone marrow-derived DCs into mice
infected with L. donovani only reduced the number of spleen and
liver amastigotes, when combined with sodium stibogluconate, the
treatment resulted in a complete eradication of the parasites from
both organs (132).
A fusion protein that stimulates T cells through OX40, as well
as a monoclonal antibody (mAb) agonist against CD40, enhanced
host immunity, and supported low-dose SbV in a murine VL
model (133, 134). The treatment enhanced both the rate of gran-
uloma maturation and CD4+ T cell proliferation and promoted
greater reduction in the parasite burden, without causing excess
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tissue damage. Moreover, the blockade of cytotoxic T lymphocyte-
associated (CTLA)-4, a negative regulator of T cell co-stimulation
using mAb, has a beneficial effect in experimental VL, inducing
the destruction of 60% of the parasites within liver macrophages,
stimulating IFN-γ secretion, and enhancing mononuclear cell
recruitment with significant synergy with SbV (134).
In VL, cytokine-mediated immunosuppression is dominated
by IL-10 and TGF-β (135). Hence IL-10-deficient mice are highly
resistant to VL (27, 135). This cytokine also impairs responsiveness
to SbV. In experimental models of VL, treatment with mAb against
the IL-10 receptor allowed a 10-fold reduction in the effective
dose of SbV compared with the drug alone, as well as considerable
shortening of the time needed for effective therapy (135, 136).
Inhibition of TGF-β has been shown to decrease parasite burdens
in experimental VL; however, TGF-β blockade has no apparent
effect on SbV activity (136).
Using lower doses of miltefosine in combination with Pam3Cys
(an immunomodulator synthetic bacterial lipopeptide (BLP) and
TLR-2/1 ligand) in a BALB/c mouse model of VL, Shakya et al.
(137) demonstrated significantly enhanced parasitic inhibition
and Th1 cytokine production and an increased phagocytosis index.
Another study, conducted by Karmakar et al. (138), demonstrated
the interactions between a TLR ligand and invariant natural killer
T (iNKT) cell activation as immunotherapy in VL. The authors
evaluated the anti-Leishmania immune responses and the protec-
tive efficacy of the b-(1–4)-galactose terminal NKT cell ligand
glycosphingophospholipid (GSPL) antigen of L. donovani par-
asites. Their findings suggested that TLR4 can function as an
upstream sensor for GSPL and promote intracellular inflamma-
tory signaling necessary for parasite killing. Furthermore, the
treatment with GSPL induced a strong, effective T cell response,
with control of acute parasite burden leading to undetectable
parasite persistence (138).
The remarkable improvement in clinical signs and decrease in
parasite burden in the immunotherapy or immunochemother-
apy protocols described mostly arise from the restoration and
activation of an effective immune response. In this context, the
search for new therapeutic vaccines or substances with strong
immunomodulatory effects as adjuvants (immunotherapy) may
lead to the next generation of drugs, and associations with con-
ventional chemotherapy (immunochemotherapy) will form the
treatment strategy to cure visceral disease or reverse severe clinical
forms of HVL.
CONCLUDING REMARKS
Most traditional and low-cost treatment options for VL are
toxic and have many side effects, and the use of more effective
drugs is limited mainly by the high cost. Successful immunother-
apy using killed parasite vaccines or immunomodulators has
been extensively reported in leishmaniasis. Another approach
is immunochemotherapy, in which a low-dose or short course
of chemotherapy associated with a vaccine or immunomodula-
tor quickly induces an effective immune response. In VL, many
efforts in the development and application of immunotherapy
or immunochemotherapy have been made in the last decade,
mainly due to the emergence of drug resistance and the increase
in HIV co-infection. Many researchers have treated CVL using
vaccines and immunomodulators with or without chemotherapy.
In humans, the use of cytokines like IFN-γ associated with SbV has
demonstrated promising results in patients that are unresponsive
to conventional treatment. In murine models, immunomodula-
tion based on mAbs to remove endogenous immunosuppressive
cytokines or block their receptors, antigen-pulsed syngeneic DCs,
and biological products like Pam3Cys (TLR ligand) has demon-
strated future prospects for the treatment of VL. Efforts need to
be directed to standardization and additional carefully controlled
studies in animals and humans to understand the immunologic
basis of these new vaccines and other immunomodulators in
conjunction with chemotherapeutic agents for treatment of this
important neglected disease.
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